CDTX (Cidara Therapeutics) היקף יתרות המזומנים של החברה

Cidara Therapeutics (CDTX) is implementing the Cloudbreak platform to develop extended-release immunotherapeutic agents. Proprietary hospital drugs ensure stable demand and procurement resilience. Independence from macroeconomic factors renders the asset a defensive asset during a recession. The free cash flow metric demonstrates business liquidity, with the value recorded at 0.40, confirming the company's current solvency.
פילוחי מדדים פיננסיים ומדדי שוק עבור cidara.com (CDTX)

Selecting assets with a high margin of safety requires an analysis of liquidity as an absolute indicator of available funds to cover operating expenses. This metric captures the current safety cushion, which is critical for Cidara Therapeutics (CDTX) when financing the development of immunotherapeutic drugs and allocating clinical trial risks, reflecting the trend of physical cash holdings.